Catalent Inc (NYSE:CTLT) – Research analysts at William Blair dropped their Q3 2018 earnings per share estimates for shares of Catalent in a research note issued to investors on Tuesday. William Blair analyst J. Kreger now forecasts that the company will post earnings of $0.36 per share for the quarter, down from their prior estimate of $0.42. William Blair also issued estimates for Catalent’s Q4 2018 earnings at $0.55 EPS, Q2 2019 earnings at $0.44 EPS, Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.66 EPS and FY2019 earnings at $1.77 EPS.
Several other equities research analysts have also commented on the company. Zacks Investment Research lowered Catalent from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Royal Bank of Canada started coverage on Catalent in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Piper Jaffray Companies upped their price objective on Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 7th. BidaskClub lowered Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, First Analysis initiated coverage on Catalent in a research note on Friday, January 5th. They issued an “equal weight” rating for the company. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $45.60.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. The firm had revenue of $606.30 million for the quarter, compared to analysts’ expectations of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company’s revenue was up 25.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.27 EPS.
Institutional investors have recently modified their holdings of the company. 361 Capital LLC lifted its holdings in shares of Catalent by 18.6% in the 3rd quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock valued at $2,795,000 after acquiring an additional 10,974 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Catalent by 25.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock valued at $41,773,000 after acquiring an additional 210,296 shares during the last quarter. Stevens Capital Management LP bought a new position in shares of Catalent in the 3rd quarter valued at about $2,475,000. Sei Investments Co. lifted its holdings in shares of Catalent by 119.1% in the 3rd quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock valued at $3,761,000 after acquiring an additional 51,212 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new position in shares of Catalent in the 3rd quarter valued at about $18,420,000. Hedge funds and other institutional investors own 98.86% of the company’s stock.
In other news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. Corporate insiders own 1.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/09/catalent-inc-ctlt-to-post-q3-2018-earnings-of-0-36-per-share-william-blair-forecasts.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.